- In September 2024, AbbVie expanded clinical trials for Upadacitinib (Rinvoq) to assess its efficacy in treating alopecia areata and ulcerative colitis
- In October 2020, announced new data supporting the long-term efficacy and safety of its JAK1 inhibitor Abrocitinib for atopic dermatitis
